Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Animals
Antineoplastic Agents, Hormonal
/ therapeutic use
Breast Neoplasms
/ drug therapy
Drug Resistance, Neoplasm
Fatty Acid Synthase, Type I
/ genetics
Female
Fulvestrant
/ therapeutic use
Humans
MAP Kinase Signaling System
MCF-7 Cells
Mice
Mice, Nude
Phosphatidylinositol 3-Kinases
/ metabolism
Proteins
/ genetics
Proto-Oncogene Proteins c-akt
/ metabolism
Receptor, ErbB-2
/ genetics
Tamoxifen
/ therapeutic use
endocrine resistance
fulvestrant
luminal
tamoxifen
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Oct 2020
16 Oct 2020
Historique:
received:
28
09
2020
revised:
12
10
2020
accepted:
14
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link them are, however, incompletely understood. Here, we evaluated the putative role of the lipogenic enzyme fatty acid synthase (FASN) as a major cause of HRG-driven endocrine resistance in ER+/HER2-negative breast cancer cells. MCF-7 cells engineered to stably overexpress HRG (MCF-7/HRG), an in vitro model of tamoxifen/fulvestrant-resistant luminal B-like breast cancer, showed a pronounced up-regulation of
Identifiants
pubmed: 33081219
pii: ijms21207661
doi: 10.3390/ijms21207661
pmc: PMC7588883
pii:
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Proteins
0
histidine-rich proteins
0
Tamoxifen
094ZI81Y45
Fulvestrant
22X328QOC4
FASN protein, human
EC 2.3.1.85
Fatty Acid Synthase, Type I
EC 2.3.1.85
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : R01 CA116623
Pays : United States
Organisme : U.S. Department of Defense
ID : BC151072
Organisme : U.S. Department of Defense
ID : BC151072P1
Organisme : Ministerio de Ciencia e Innovación
ID : SAF2016-80639-P
Organisme : Ministerio de Ciencia e Innovación
ID : PID2019-10455GB-I00
Références
Steroids. 2009 Jul;74(7):586-94
pubmed: 19138696
J Clin Oncol. 2006 Aug 10;24(23):3735-46
pubmed: 16847284
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016
pubmed: 28922023
Cancer Res. 2003 Jan 1;63(1):132-9
pubmed: 12517789
Front Endocrinol (Lausanne). 2019 Aug 21;10:573
pubmed: 31496995
Mol Endocrinol. 2001 Oct;15(10):1817-28
pubmed: 11579213
Oncogenesis. 2017 Feb 27;6(2):e299
pubmed: 28240737
Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):185-97
pubmed: 22338595
Breast Cancer Res Treat. 1996;38(1):57-66
pubmed: 8825123
Future Med Chem. 2015 Aug;7(12):1511-9
pubmed: 26306654
Int J Mol Sci. 2020 Mar 12;21(6):
pubmed: 32178271
Breast Cancer. 2018 Jul;25(4):392-401
pubmed: 29086897
Hematol Oncol Clin North Am. 2013 Aug;27(4):703-14, vii-viii
pubmed: 23915740
J Agric Food Chem. 2007 Jun 27;55(13):5030-7
pubmed: 17539658
Oncoscience. 2016 Jul 22;3(7-8):242-257
pubmed: 27713913
Oncology. 2009;77 Suppl 1:23-37
pubmed: 20130429
Breast Cancer Res. 2018 Sep 4;20(1):106
pubmed: 30180878
Endocrinology. 1996 Oct;137(10):4322-30
pubmed: 8828492
Endocr Relat Cancer. 2011 Jul 04;18(4):C19-24
pubmed: 21613412
Breast Cancer Res. 2014 Dec 12;16(6):494
pubmed: 25928204
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32961983
FASEB J. 2020 Aug 6;:
pubmed: 32761847
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12975-80
pubmed: 9371785
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
Histol Histopathol. 2017 Jul;32(7):687-698
pubmed: 27714708
J Clin Oncol. 2007 Apr 1;25(10):1239-46
pubmed: 17401012
Oncogene. 2000 Oct 26;19(45):5173-81
pubmed: 11064454
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
Cancer Res. 1996 Jul 15;56(14):3350-8
pubmed: 8764133
Int J Cancer. 2015 May 1;136(9):2078-90
pubmed: 25302649
Oncotarget. 2016 Nov 1;7(44):71151-71168
pubmed: 27223424
Int J Mol Sci. 2014 Jun 27;15(7):11539-54
pubmed: 24979135
Oncogene. 2003 May 29;22(22):3441-51
pubmed: 12776196
Mol Carcinog. 2004 Nov;41(3):164-78
pubmed: 15390078
Clin Cancer Res. 2015 Dec 15;21(24):5434-8
pubmed: 26519059
EMBO Rep. 2019 Feb;20(2):
pubmed: 30665944
BMC Med Genomics. 2009 Jun 24;2:37
pubmed: 19552798